Apoptin induces apoptosis in nude mice allograft model of human bladder cancer by altering multiple bladder tumor-associated gene expression profiles

Tumor Biology

Volumn 34, Issue 3, 2013, Pages 1667-1678

  Wang, Chunhui ^a   Wang, Wenju ^a   Wang, Jiansong ^a   Zhan, Hui ^a   Jiang, Lihong ^a   Yan, Ruping ^a   Hou, Zongliu ^a   Zhu, Huirong ^a   Yu, Lirui ^a   Shi, Yunqiang ^a   Ding, Mingxia ^a   Ke, Changxing ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptin; Bladder carcinomas; Selective cytotoxic effect; Tumor associated genes

Indexed keywords

ADENOVIRUS VECTOR; APOPTIN; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; LIPOCORTIN 5; NUCLEOSIDE DIPHOSPHATE KINASE NM23; RETINOBLASTOMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER GENE THERAPY; CANCER PROGNOSIS; CELL VIABILITY; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; FLOW CYTOMETRY; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; KI 67 GENE; MOUSE; NONHUMAN; NUCLEOSIDE DIPHOSPHATE KINASE NM23 GENE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WESTERN BLOTTING;

EID: 84878728710     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0700-8     Document Type: Article

References (30)

1. Burger M, Catto J W F, Dalbagni G, Grossman H B, Herr H, Karakiewicz P, Kassouf W, Kiemeney L A, La Vecchia CShariat S. Epidemiology and risk factors of urothelial bladder cancer. European urology. 2012
2. Philips BJ, Coyle CH, Morrisroe SN, Chancellor M, BYoshimura N. Induction of apoptosis in human bladder cancer cells by green tea catechins. Biomed Res. 2009;30:207-15.
3. Malkowicz SB. Intravesical therapy for superficial bladder cancer. Semin Urol Oncol. 2000;18:280-8.
4. Pan JG, Zhou X, Zeng G, WHan RF. Suppression of bladder cancer growth in mice by adeno-associated virus vector-mediated endostatin expression. Tumor Biology. 2011;32:301-10.
5. Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother. 2007;61:299-305.
6. Matsumoto K, Kikuchi E, Horinaga M, Takeda T, Miyajima A, Nakagawa KOya M. Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model. Human Gene Therapy. 2011;22:1423-32.
7. Los M, Panigrahi S, Rashedi I, Mandal S, Stetefeld J, Essmann FSchulze-Osthoff K. Apoptin, a tumor-selective killer. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2009;1793:1335-42.
8. Rohn JNoteborn M. The viral death effector apoptin reveals tumor-specific processes. Apoptosis. 2004;9:315-22.
9. Zhou S, Zhang M, Zhang J, Shen H, Tangsakar EWang J. Mechanisms of apoptin-induced cell death. Medical Oncology. 2011;1-7
10. Pietersen ANoteborn M H M. Apoptin®. Cancer Gene Therapy. 2002;153-161
11. Poon I, Oro C, Dias M, Zhang J, PJans D. A tumor cell-specific nuclear targeting signal within chicken anemia virus VP3/apoptin. J Virol. 2005;79:1339-41.
12. Danen-Van Oorschot A, Fischer D, Grimbergen JM, Klein B, Zhuang SM, Falkenburg J, et al. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci. 1997;94:5843-7.
13. Zhuang SM, Shvarts A, van Ormondt H, Jochemsen AG, van der Eb A, JNoteborn MHM. Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. Cancer Res. 1995;55:486-9.
14. Danen-van Oorschot A, van Der Eb ANoteborn M. The chicken anemia virus-derived protein apoptin requires activation of caspases for induction of apoptosis in human tumor cells. J Virol. 2000;74:7072-8.
15. Danen-Van Oorschot AA, van der Eb AJ, Noteborn MH. BCL-2 stimulates apoptin-induced apoptosis. Adv Exp Med Biol. 1999;457:245-9.
16. Danen-Van Oorschot AA, Zhang Y, Erkeland SJ, Fischer DF, van der Eb AJ, Noteborn MH. The effect of Bcl-2 on Apoptin in 'normal' vs. transformed human cells. Leukemia. 1999;13(1):S75-7.
17. Takahashi R, Hashimoto T, Xu HJ, Hu SX, Matsui T, Miki T, et al. The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. Proc Natl Acad Sci. 1991;88:5257.
18. Enache M, SIMIONESCU CLASCU LC. Ki67 and Bcl-2 immunoexpression in primitive urothelial bladder carcinoma. Romanian journal of morphology and embryology. Revue Roumaine de Morphologie et Embryologie. 2012;53:521.
19. Fleischmann A, Rotzer D, Seiler R, Studer U, EThalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol. 2011;60:350-7.
20. Krause FS, Feil G, Bichler KH. Immunohistochemical examinations (Ki67, p53, nm23) and DNA cytophotometry in bladder cancer. Anticancer Res. 2000;20:5023-8.
21. Desilet N, Campbell TN, Choy FY. p53-based anti-cancer therapies: an empty promise? Curr Issues Mol Biol. 2010;12:143-6.
22. Burdelya LG, Komarova EA, Hill JE, Browder T, Tararova ND, Mavrakis L, et al. Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res. 2006;66:9356-61.
23. Noteborn M. Apoptin®-induced apoptosis: a review. Apoptosis. 1999;4:317-9.
24. Lara PC, Rey A, Santana C, Afonso JL, Diaz JM, González GApolinario R. The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy. Radiother Oncol. 1998;49:163-7.
25. Teodoro JG, Heilman DW, Parker A, EGreen MR. The viral protein apoptin associates with the anaphase-promoting complex to induce G2/M arrest and apoptosis in the absence of p53. Genes Dev. 2004;18:1952-7.
26. Grossman HB, Liebert M, Antelo M, Dinney C, Hu SX, Palmer J, et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res. 1998;4:829-34.
27. Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, et al. ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS One. 2011;6:e27616.
28. Wright C, Mellon K, Neal D, Johnston P, Corbett I, Horne C. Expression of c-erbB-2 protein product in bladder cancer. Br J Cancer. 1990;62:764.
29. Marín ÁP, Arranz EE, Sánchez AR, Auñón PZ, Barón MG. Role of anti-Her-2 therapy in bladder carcinoma. J Cancer Res Clin Oncol. 2010;136:1915-20.
30. Chow NH, Liu HS, Chan SH. The role of nm23-H1 in the progression of transitional cell bladder cancer. Clin Cancer Res. 2000;6:3595-9.